STOCK TITAN

X4 Pharmaceuticals (XFOR) Stock News, May-Aug 2023

XFOR NASDAQ

X4 Pharmaceuticals, Inc. develops and commercializes therapies for rare hematology diseases, centered on mavorixafor, an oral CXCR4 antagonist marketed in the U.S. as XOLREMDI® in its first indication. Company news covers regulatory and commercial updates for XOLREMDI, including European authorization for WHIM syndrome and the Norgine license and supply relationship for selected ex-U.S. territories.

Recurring updates also address the 4WARD Phase 3 program evaluating mavorixafor in chronic neutropenia, quarterly financial results, product revenue, research and development spending, cash resources, restructuring effects, conference participation, and equity inducement grants under Nasdaq listing rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.98%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.30%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
conferences earnings
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.69%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
none
-
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.79%
Tags
private placement
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags

FAQ

What is the current stock price of X4 Pharmaceuticals (XFOR)?

X4 Pharmaceuticals (XFOR) last closed at $3.09.

What is the market cap of X4 Pharmaceuticals (XFOR)?

The market cap of X4 Pharmaceuticals (XFOR) is approximately $315.5M.